Presentation is loading. Please wait.

Presentation is loading. Please wait.

Dr. Jean-Hervé Bradol Research Director MSF Center for Reflection on Humanitarian Action & Knowledge Medical Innovation in Humanitarian Situations: The.

Similar presentations


Presentation on theme: "Dr. Jean-Hervé Bradol Research Director MSF Center for Reflection on Humanitarian Action & Knowledge Medical Innovation in Humanitarian Situations: The."— Presentation transcript:

1 Dr. Jean-Hervé Bradol Research Director MSF Center for Reflection on Humanitarian Action & Knowledge Medical Innovation in Humanitarian Situations: The Work of Médecins Sans Frontières

2

3

4

5

6

7 MSF Malaria Studies More than 12,000 patients were enrolled in 43 efficacy studies in 18 countries of Asia and Africa between 1996 and This accounted for 1/4 of the overall research output in these countries during that period. The vast majority of the studies were published in peer-reviewed journals Guthmann J.-P., Checchi F. et al., 2008, « Assessing Antimalarial Efficacy in a time of Change to Artemisinine-Based Combination Therapies : The Role of Médecins Sans Frontières », Plos Medicine, 5 (8), p

8

9

10

11 Requirements to be met: The treatment must be accepted by the WHO Reliable supply sources must be identified – they must be sustainable, of good quality and reasonably priced Economic conditions must be created to finance the new protocol Legal questions must be addressed (intellectual property) Administrative authorisations from national authorities must be obtained on import and use New treatment protocols must be written and staff trained

12

13

14

15 Medical Innovation in Humanitarian Situations The Work of Médecins Sans Frontières Edited by Jean-Hervé Bradol and Claudine Vidal Innovations? Jean-Hervé Bradol and Marc Le Pape MSF satellites. A strategy underlying different medical practices Claudine Vidal and Jacques Pinel Measure, analyse, publish and innovate Emmanuel Baron Controversy policy Marc Le Pape and Isabelle Defourny Remarks Nicolas Dodier Cholera: diagnosis and treatment outside the hospital Jean François Corty Meningitis: from practitioner to prescriber Eugénie dAlessandro Human African trypanosomiasis: moving beyond arsenic Jean François Corty Malaria: resistances treated by south-south mediation Suna Balkan and Jean-François Corty AIDS: a new pandemic requiring new medical and political practices Jean-Hervé Bradol and Elizabeth Szumilin

16 Tropical diseases: 18 Source: Chirac P, Torreele E. Lancet May 12; New drugs developed from Tropical diseases and tuberculosis account for 12% of the global disease burden, but only 1.3% of new drugs developed. TB: 3 1.3%1.3% Total: 1,556

17 Launch & utilization CHALLENGE 3 CHALLENGE 4 Specific Activities Organizations TDR Unspecified GSK WRAIR 2000: A Deserted R&D Landscape Screening Lead identification Lead optimization In vivo efficacy Regulatory toxicity & safety Phase 1 Phase 2 Phase 3 Registration Cutaneous Leishmaniasis CHALLENGE 1 CHALLENGE 2 Visceral Leishmaniasis HAT Chagas CHALLENGE 3 Launch & utilization CHALLENGE 4

18 Screening Lead identification Lead optimization In vivo efficacy Regulatory toxicity & safety Phase 1 Phase 2 Phase 3 Registration Launch & utilization HATChagas Visceral Leishmaniasis Cutaneous Leishmaniasis DengueMalaria TB CHALLENGE 1 Sandler Center IOWH MMV GSK CDND TB Alliance DNDi Specific Activities Organizations TDR NITD – PC dengue, TB CHALLENGE 2 CHALLENGE 3 CHALLENGE 4 Unspecified WRAIR 2007 Drug R&D Landscape for NTDs

19 Combined PDP pipeline today includes 143 candidates 7Feasibility 7 Test Development 6Evaluation 1Demonstration 6 Country Adoption CD4 FIND IDRI Notes: Includes products not funded by Gates Foundation. Biopharmaceutical candidates in development Include: IAVI, IPM, IVI, GATB, Aeras, MMV, MVI, MVP, PVS, DNDi, iOWH, PDVI, HHVI. Source: PDPs 4% 22% 26% 22% 104 biopharmaceutical candidates in development and 39 diagnostic & vector control candidates 59Pre Clinical 15Phase I 12Phase II 10Phase III 2Registration 6Launched Drugs Vaccines Microbicides # candidates 10% 12% 14% 57% 6% 2% Early Stage In Development IVCC # candidates Diagnostics Vector control 26% 8

20 20 Product Development Partnerships (PDPs): Filling the Gaps in Translational Research and Product Development


Download ppt "Dr. Jean-Hervé Bradol Research Director MSF Center for Reflection on Humanitarian Action & Knowledge Medical Innovation in Humanitarian Situations: The."

Similar presentations


Ads by Google